PMID- 36915508
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230315
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 3
DP  - 2023 Mar
TI  - Apigenin-coated gold nanoparticles as a cardioprotective strategy against 
      doxorubicin-induced cardiotoxicity in male rats via reducing apoptosis.
PG  - e14024
LID - 10.1016/j.heliyon.2023.e14024 [doi]
LID - e14024
AB  - AIMS: Cardiotoxicity is associated with doxorubicin (DOX), an effective 
      anticancer drug. Apigenin has cardioprotective properties; it may be employed as 
      a capping and reducing agent in synthesizing gold nanoparticles (AuNPs). This 
      study examined the cardioprotective impact of AuNPs synthesized with apigenin 
      (Api) in DOX-induced cardiotoxicity (DIC). MAIN METHODS: Api-AuNPs were 
      synthesized in a single pot without needing additional reagents for reducing gold 
      ions or stabilizing the NPs. The cytotoxicity of Api-AuNPs on H9c2 heart cells 
      was subsequently determined using the MTT assay. In the animal investigation, 40 
      male rats were randomly assigned to one of four groups: control, cardiotoxicity 
      (DOX), DOX treated with apigenin (DOX + Api), or DOX treated with Api-AuNPs 
      (DOX + Api-AuNPs). To examine heart function, echocardiography was conducted. 
      Blood samples were obtained to evaluate injury indicators (Lactate dehydrogenase 
      (LDH), creatine kinase MB (CK-MB), Cardiac Troponin I (cTn-I), Alanine 
      transaminase (ALT), and Aspartate transaminase (AST)). The heart was removed 
      under general anesthetic, weighed, and preserved in formalin solution. Six 
      micrometer-thick cardiac tissue sections were stained with hematoxylin, eosin 
      (H&E), and immunohistochemistry to identify cardiomyocyte apoptotic markers (Bax, 
      Bcl-2, and caspase3). KEY FINDINGS: Api-AuNPs have an average size of 
      21.4 +/- 11.6 nm and are stable in physiological environments. Api-AuNPs therapy 
      substantially reduced body and heart weight loss compared to the DOX group. 
      Injury indicators were reduced dramatically by Api-AuNPs treatment. Api-AuNPs 
      inhibited myocardial apoptosis via modulating Bax, caspase3, and Bcl-2 and 
      ameliorating tissue damage caused by DOX. SIGNIFICANCE: Api-AuNPs' anti-apoptotic 
      activities provide cardioprotection against DIC. It has the potential to reduce 
      cardiotoxicity and boost myocardial performance.
CI  - (c) 2023 The Authors.
FAU - Sharifiaghdam, Zeynab
AU  - Sharifiaghdam Z
AD  - Department of Physiology, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Amini, Seyed Mohammad
AU  - Amini SM
AD  - Radiation Biology Research Center, Iran University of Medical Sciences (IUMS), 
      Tehran, Iran.
FAU - Dalouchi, Fereshteh
AU  - Dalouchi F
AD  - Department of Physiology, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Behrooz, Amir Barzegar
AU  - Behrooz AB
AD  - Nanobiotechnology Research Group, Department of Biochemistry, Faculty of 
      Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang 43400, 
      Malaysia.
AD  - Electrophysiology Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Azizi, Yaser
AU  - Azizi Y
AD  - Department of Physiology, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
AD  - Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230224
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10006676
OTO - NOTNLM
OT  - Apigenin
OT  - Apoptosis
OT  - Cardiotoxicity
OT  - Doxorubicin
OT  - Gold nanoparticles
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/15 06:00
MHDA- 2023/03/15 06:01
PMCR- 2023/02/24
CRDT- 2023/03/14 02:07
PHST- 2022/10/11 00:00 [received]
PHST- 2023/02/09 00:00 [revised]
PHST- 2023/02/20 00:00 [accepted]
PHST- 2023/03/14 02:07 [entrez]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/15 06:01 [medline]
PHST- 2023/02/24 00:00 [pmc-release]
AID - S2405-8440(23)01231-8 [pii]
AID - e14024 [pii]
AID - 10.1016/j.heliyon.2023.e14024 [doi]
PST - epublish
SO  - Heliyon. 2023 Feb 24;9(3):e14024. doi: 10.1016/j.heliyon.2023.e14024. eCollection 
      2023 Mar.